Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.